Scandinavian ChemoTech’s TSE Treatment Shows High Response Rate in Veterinary Cancer Study — Validated by Approved PhD Dissertation
24 juli, 16:25
Scandinavian ChemoTech’s TSE Treatment Shows High Response Rate in Veterinary Cancer Study — Validated by Approved PhD Dissertation
Regulatory press release
Lund, Sweden 24 July 2025
A recent PhD dissertation confirms that Tumour Specific Electroporation (TSE) is a safe and highly effective cancer therapy for dogs and cats, with response rates of up to 100%.
Scandinavian ChemoTech AB (publ) is proud to announce that a PhD dissertation authored by veterinary researcher SimgeBayraktar has validated the company’s Tumour Specific Electroporation (TSE) technology as a safe and effective local treatment for cancer in companion animals. The dissertation was formally approved by the PhD Dissertation Board University-Cerrahpaşa (Veterinary Faculty Surgery Department) (iuc.edu.tr) and reports objective tumor response rates ranging from 72% to 100% in treated animals.
The study, titled "Tumour Specific Electroporation (TSE) for the Local Management of Superficial Tumors in Companion Animals: A Retrospective Study of 30 Cases", included 15 dogs and 15 cats, with a follow-up period of 12 months. It confirms that TSE can be used in curative, adjuvant, and palliative settings. The treatment was well tolerated with minimal side effects, making it an attractive alternative or complement to traditional oncology treatments like surgery or chemotherapy — especially when those options are limited or not viable.
“This academic milestone provides strong scientific support for our Tumour Specific Electroporation (TSE) technology in veterinary oncology,” said Mohan Frick, CEO and co-founder of Scandinavian ChemoTech. “It confirms what we have seen in clinical practice — that TSE offers a safe, minimal-invasive, and effective treatment option even for advanced or challenging tumor cases. We are incredibly proud of Simge Bayraktar’s contribution and the growing momentum behind TSE. We are currently awaiting publication of the full article and look forward to sharing the complete results once available. This publication will be important in further validating the clinical outcomes that our veterinarians are already seeing in practice.”
The retrospective study analyzed 30 companion animals with superficial tumors of various types and histological characteristics. Breeds included Golden Retrievers, Pugs, British Shorthairs, and mixed breeds. All cases were evaluated using the RECIST guidelines (Response Evaluation Criteria in Solid Tumors) with a follow-up period of 12 months.
“It was an honor to work with such an innovative therapy as Tumour Specific Electroporation (TSE) and to witness firsthand how it improves the quality of life in animals facing serious illness,” said PhD. DVM Simge Bayraktar.
“As a veterinarian, it’s incredibly rewarding to use a method that not only delivers strong clinical results but also impresses even the most established and experienced professors, both clinically and scientifically. This study has further strengthened my belief that TSE will play a vital role in the future of veterinary oncology.”
With the dissertation now approved, VQ Animal Care Inc. (Scandinavian ChemoTech’s animal care company) views this as significant validation to support expanded clinical adoption, strengthen strategic partnerships, and reinforce its leadership in the emerging field of veterinary electrochemotherapy.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 24-07-2025 16:25 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB,
Ämnen i artikeln
Scandinavian ChemoTech’s TSE Treatment Shows High Response Rate in Veterinary Cancer Study — Validated by Approved PhD Dissertation
24 juli, 16:25
Scandinavian ChemoTech’s TSE Treatment Shows High Response Rate in Veterinary Cancer Study — Validated by Approved PhD Dissertation
Regulatory press release
Lund, Sweden 24 July 2025
A recent PhD dissertation confirms that Tumour Specific Electroporation (TSE) is a safe and highly effective cancer therapy for dogs and cats, with response rates of up to 100%.
Scandinavian ChemoTech AB (publ) is proud to announce that a PhD dissertation authored by veterinary researcher SimgeBayraktar has validated the company’s Tumour Specific Electroporation (TSE) technology as a safe and effective local treatment for cancer in companion animals. The dissertation was formally approved by the PhD Dissertation Board University-Cerrahpaşa (Veterinary Faculty Surgery Department) (iuc.edu.tr) and reports objective tumor response rates ranging from 72% to 100% in treated animals.
The study, titled "Tumour Specific Electroporation (TSE) for the Local Management of Superficial Tumors in Companion Animals: A Retrospective Study of 30 Cases", included 15 dogs and 15 cats, with a follow-up period of 12 months. It confirms that TSE can be used in curative, adjuvant, and palliative settings. The treatment was well tolerated with minimal side effects, making it an attractive alternative or complement to traditional oncology treatments like surgery or chemotherapy — especially when those options are limited or not viable.
“This academic milestone provides strong scientific support for our Tumour Specific Electroporation (TSE) technology in veterinary oncology,” said Mohan Frick, CEO and co-founder of Scandinavian ChemoTech. “It confirms what we have seen in clinical practice — that TSE offers a safe, minimal-invasive, and effective treatment option even for advanced or challenging tumor cases. We are incredibly proud of Simge Bayraktar’s contribution and the growing momentum behind TSE. We are currently awaiting publication of the full article and look forward to sharing the complete results once available. This publication will be important in further validating the clinical outcomes that our veterinarians are already seeing in practice.”
The retrospective study analyzed 30 companion animals with superficial tumors of various types and histological characteristics. Breeds included Golden Retrievers, Pugs, British Shorthairs, and mixed breeds. All cases were evaluated using the RECIST guidelines (Response Evaluation Criteria in Solid Tumors) with a follow-up period of 12 months.
“It was an honor to work with such an innovative therapy as Tumour Specific Electroporation (TSE) and to witness firsthand how it improves the quality of life in animals facing serious illness,” said PhD. DVM Simge Bayraktar.
“As a veterinarian, it’s incredibly rewarding to use a method that not only delivers strong clinical results but also impresses even the most established and experienced professors, both clinically and scientifically. This study has further strengthened my belief that TSE will play a vital role in the future of veterinary oncology.”
With the dissertation now approved, VQ Animal Care Inc. (Scandinavian ChemoTech’s animal care company) views this as significant validation to support expanded clinical adoption, strengthen strategic partnerships, and reinforce its leadership in the emerging field of veterinary electrochemotherapy.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 24-07-2025 16:25 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB,
Ämnen i artikeln
Handelskrig
Apple
Analys
Handelskrig
Mest läst
Apple
Analys
Senaste nytt
Kempower
Igår, 12:28
Laddat för tillväxt i Kempower
Marknadsöversikt
OMX Stockholm 30
1 DAG %
−1,80%
Senast
2 533,59
1 mån
Loading market data...
Privatekonomi med Placeras expert
Affärsvärlden
